Structure Therapeutics Reports Positive Data From Oral Amylin And GLP-1 Programs

Structure Therapeutics reported positive clinical data for its two lead oral small-molecule chronic weight-management candidates: ACCG-2671, a dual amylin and calcitonin receptor agonist, and aleniglipron, an oral GLP-1 receptor agonist. The favorable readouts support the company’s obesity-treatment pipeline and could be a meaningful positive catalyst for GPCR shares, though the article provides no efficacy, safety, or trial-size figures.